



EV 506438425 US

PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/777,488		
		Filing Date	February 12, 2004		
		First Named Inventor	Adnan M.M. Mjalli		
		Art Unit	1626		
		Examiner Name	Laura Stockton		
Sheet	1	of	1	Attorney Docket Number	TTP 2002-08

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LLS	TR-226	LIPSHUTZ et al., "Metalation Studies of Trisubstituted Oxazoles", Journal of Organic Chemistry, Vol. 46, pages 1410-1413, (1981)	
LLS	TR-225	NAKAYAMA et al., "MexAB-OprM-Specific Efflux Pump Inhibitors in Pseudomonas aeruginosa. Part 1: Discovery and Early Strategies for Lead Optimization", Bioorganic & Medicinal Chemistry Letters, Vol. 13, pages 4201-4204, (2003)	

Examiner Signature	/Laura L. Stockton/	Date Considered	01/18/2007
-----------------------	---------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 841058245 US

PTO/SB/08a (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 3

Complete If Known

Application Number	10/777,488
Filing Date	February 12, 2004
First Named Inventor	Adnan M.M. Mjalli
Art Unit	1626
Examiner Name	Laura Stockton
Attorney Docket Number	TTP 2002-08

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
LLS	TR-333	US- 2005-0014805	01/20/2005	Zhang et al.	
	TR-350	US- 2004-0188151	09/23/2004	Mjalli et al.	
	TR-351	US- 2004-0192743	09/30/2004	Mjalli et al.	
	TR-352	US- 2004-0082542	04/29/2004	Mjalli et al.	
	TR-734	US- 5,106,732	04/21/1992	Kondo et al.	
	TR-735	US- 5,510,362	04/23/1996	Matassa et al.	
	TR-736	US- 5,616,601	04/01/1997	Khanna et al.	
	TR-737	US- 5,700,816	12/23/1997	Isakson et al.	
	TR-738	US- 5,753,687	05/19/1998	Mjalli et al.	
	TR-739	US- 5,840,721	11/24/1998	Mjalli et al.	
	TR-740	US- 5,958,957	09/28/1999	Andersen et al.	
	TR-741	US- 5,972,986	10/26/1999	Seibert et al.	
	TR-742	US- 5,990,148	11/23/1999	Isakson et al.	
	TR-743	US- 6,136,839	10/24/2000	Isakson et al.	
	TR-744	US- 6,159,944	12/12/2000	McDonald et al.	
	TR-745	US- 6,285,426	07/24/2001	Alanine et al.	
	TR-746	US- 6,358,634	03/19/2002	Igarashi et al.	
	TR-747	US- 6,589,953	07/08/2003	Perez et al.	
	TR-748	US- 6,627,647	09/30/2003	Betageri	
	TR-749	US- 2003-0220372	11/27/2003	Hirano et al.	
	TR-750	US- 2004-0167187	08/26/2004	Saunders et al.	
	TR-751	US- 2004-0176395	09/09/2004	Flynn et al.	
	TR-752	US- 2004-0180906	09/16/2004	Flynn et al.	
LLS	TR-753	US- 2005-0272778	12/08/2005	Combs et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ² - Number ³ - Kind Code ⁴ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁵
LLS	TR-414	JP 09040651	02/10/1997	Yasushi et al.		✓
	TR-417	JP 2003313170	11/06/2003	Takahashi et al.		✓
	TR-418	JP 2003313172	11/06/2003	Takahashi et al.		✓
	TR-754	JP 05261293	10/12/1993	Benazzi et al.		✓
	TR-755	JP 63276054	11/14/1988	Shigeo et al.		
	TR-756	WO 199417059	08/04/1994	Miyazawa et al.		
	TR-757	WO 199641626	12/27/1996	Isakson et al.		
	TR-758	WO 199816227	4/23/1998	Seibert et al.		
	TR-759	WO 199851673	11/19/1998	Earnshaw et al.		
	TR-760	WO 200027826	05/18/2000	Lehmann-Lintz et al.		
	TR-761	WO 2004069394	08/19/2004	Sames et al.		
	TR-762	WO 2004094395	11/04/2004	Chakravarty et al.		
LLS	TR-764	CA 2158529	03/27/1996	Marten et al.		

Examiner
Signature

/Laura L. Stockton/

Date
Considered

01/18/2007

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Do not file through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ¹ See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ² Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the right of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to be (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. The collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1430, Alexandria, VA 22313-1430.

If you need assistance in completing this form, call 1-800-PTO-4199 and select option 2.

EV 841058245 US

PTO/SB/08b(08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2

of

3

Complete if Known

Application Number	10/777,488
Filing Date	February 12, 2004
First Named Inventor	Adnan M.M. Mjalli
Art Unit	1626
Examiner Name	Laura Stockton
Attorney Docket Number	TTP 2002-08

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LLS	TR-47	TAYLOR SD, "Inhibitors of protein tyrosine phosphatase 1B (PTP1B)." Current Topics in Medicinal Chemistry, 3:759-782 (2003)	
	TR-48	TAO J, "Insulin stimulates tyrosine phosphorylation and inactivation of protein-tyrosine phosphatase 1B in vivo." The Journal of Biological Chemistry, 276:29520-29525 (2001)	
	TR-49	DADKE S, "Interaction of protein tyrosine phosphatase (PTP) 1B with its substrates is influenced by two distinct binding domains." Biochemical Journal, 364:377-383 (2002)	
	TR-51	BLANCHETOT C, "Intra- and intermolecular interactions between intracellular domains of receptor protein-tyrosine phosphatases." The Journal of Biological Chemistry, 277:47263-47269 (2002)	
	TR-52	HAASE H, "Intracellular zinc fluctuations modulate protein tyrosine phosphatase activity in insulin/insulin-like growth factor-1 signaling." Experimental Cell Research, 291:289-298 (2003)	
	TR-53	LILJEBRIS C, "Investigation of potential bioisosteric replacements for the carboxyl groups of peptidomimetic inhibitors of protein tyrosine phosphatase 1B: Identification of a tetrazole-containing inhibitor with cellular activity." Journal of Medicinal Chemistry, 45:1785-1798 (2002)	
	TR-54	FRIMURER TM, "Ligand-induced conformational changes: improved predictions of ligand binding conformations and affinities." Biophysical Journal, 84:2273-2281 (2003)	
	TR-55	TJERNBERG A, "Mechanism of action of pyridazine analogues on protein tyrosine phosphatase 1B (PTP1B)" Bioorganic & Medicinal Chemistry Letters, 14:891-895 (2004)	
	TR-56	LARSEN SD, "Modification of the N-terminus of peptidomimetic protein tyrosine phosphatase 1B (PTP1B) inhibitors: identification of analogues with cellular activity." Bioorganic & Medicinal Chemistry Letters, 13:971-975 (2003)	
	TR-57	SALMEEN A, "Molecular basis for the dephosphorylation of the activation segment of the insulin receptor by protein tyrosine phosphatase 1B." Molecular Cell, 6:1401-1412 (2000)	
	TR-58	UMEZAWA K, "Molecular design and biological activities of protein-tyrosine phosphatase inhibitors." Pharmacology & Therapeutics, 99:15-24 (2003)	
	TR-346	COCCO et al., "L-Acylaminoimidazoles Synthesis and Antimicrobial Activity", Farmaco, vol. 47, no. 2, pages 229-238, (1992)	
	TR-347	International Search Report for PCT application PCT/US2005/004590 mailed September 8, 2005.	
	TR-348	LAUFER et al., "Imidazole Inhibitors of Cytokine Release: Probing Substituents in the 2 Position", vol. 45, pages 4695-4705, (2002)	
	TR-349	LIPSHUTZ et al., "Metalation Studies of Trisubstituted Oxazoles", Journal of Organic Chemistry, vol. 48, pages 1410-1413, (1981)	
✓	TR-350-A	MEANWELL et al., "Nonprostanoid prostacyclin mimetics. 2. 4, 5-Diphenyloxazole derivatives", Journal of Medicinal Chemistry, vol. 35, no. 19, pages 3483-3497, (1992)	
LLS	TR-763	Combs et al., "Structure-based design and discovery of protein tyrosine phosphatase inhibitors incorporating novel isothiazolidinone heterocyclic phosphotyrosine mimetics" Journal of Medicinal Chemistry, Vol. 48, pp. 6544-6548 (2005).	

Examiner Signature	/Laura L. Stockton/	Date Considered	01/18/2007
--------------------	---------------------	-----------------	------------

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached.
 This collection of information is required by 37 CFR 1.06. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-0199 and select option 2.

EV 841058245 US

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form-1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	3	of	3
-------	---	----	---

Complete if Known

Application Number	10/777,488
Filing Date	February 12, 2004
First Named Inventor	Adnan M.M. Mjalli
Art Unit	1626
Examiner Name	Laura Stockton
Attorney Docket Number	TTP 2002-08

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
LLS	TR-334	EP 1 227 084	07/31/2002	Leger et al.		
	TR-335	EP 1 253 142	10/30/2002	Takemoto et al.		
	TR-336	EP 1 452 530	09/01/2004	Inaba et al.		
	TR-337	JP 2002-114768	04/16/2002	Takeshi et al.		✓
	TR-338	JP 2003-231679	08/19/2003	Atsunori et al.		✓
	TR-339	WO 1994-008982	04/28/1994	Kumita et al.		
	TR-340	WO 2000-071120	11/30/2000	Heerding et al.		
	TR-341	WO 2003-075921	09/18/2003	Mjalli et al.		
	TR-342	WO 2003-093263	11/13/2003	Maynard et al.		
	TR-343	WO 2004-013141	02/12/2004	Luke et al.		
	TR-344	WO 2004-063169	07/29/2004	Urano et al.		
	TR-345	WO 2004-089918	10/21/2004	Ikemoto et al.		
LLS	TR-766	EP 1 553 091	07/13/2005	Ikemoto et al.		

**Examiner
Signature**

/Laura L. Stockton/

Date
Considered

01/18/2007

EXAMINER: Initial a reference considered, whether or not citation is in conformance with MPEP 808. Draw time through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹
 Applicant's unique citation designation number (optional):² See Kinds Code of USPTO Patent Documents at www.uspto.gov or MPEP P01.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).
 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.⁴ Applicant is to place a check mark here if English language Translation is attached.
 This collection of information is required by 37 CFR 1.67 and 1.68. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the content of this form to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-5050. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete If Known	
				Application Number	10/777,488
				Filing Date	02/12/04
				First Named Inventor	Adnan M.M. Mjalli
				Art Unit	1614
				Examiner Name	Unkown
				Attorney Docket Number	TTP 2002-08
Sheet	2	of	19		

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
LLS	TR-147	WO 03/041729	05/22/03	Zhang et al.		
↓	TR-148	WO 03/048140	06/12/03	Inaba et al.		
	TR-149	WO 03/064376	08/07/03	Swinnen et al.		
	TR-150	WO 03/072537	09/04/03	Szezepankiewicz et al.		
	TR-151	WO 03/073987	09/12/03	Barr et al.		
	TR-152	WO 03/082841	10/09/03	Coppola et al.		
	TR-153	WO 03/092679	11/13/03	Groneberg et al.		
	TR-154	WO 03/093498	11/13/03	Pei et al.		
LLS	TR-156	WO 04/020466	03/11/04	Hooft et al.		

Examiner Signature	/Laura L. Stockton/	Date Considered	01/18/2007
-----------------------	---------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1448A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 3 of 19**Complete If Known**

Application Number	10/777,488
Filing Date	02/12/04
First Named Inventor	Adnan M.M. Mjalli
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	TTP 2002-08

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
LLS	TR-157	WO 04/041799	05/21/04	Birch et al.		
	TR-158	WO 04/050646	06/17/04	Kenny et al.		
	TR-159	WO 04/071447	08/26/04	Mjalli et al.		
	TR-160	WO 04/071448	08/26/04	Mjalli et al.		
	TR-161	WO 04/074238	09/02/04	Gray et al.		
LLS	TR-162	WO 04/074256	09/02/04	Klopfenstein et al.		

Examiner Signature	/Laura L. Stockton/	Date Considered	01/18/2007
-----------------------	---------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9189 and select option 2.

NOV 30 2004
U.S. PATENT & TRADEMARK OFFICE

PTO/SB/08a (08-03)

Approved for use through 07/31/2008, OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 19

Complete if Known

Application Number	10/777,488
Filing Date	02/12/04
First Named Inventor	Adnan M.M. Mjalli
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	TTP 2002-08

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)				
LLS	TR-131	US- 5,972,978		10/28/1999	Andersen et al.	
	TR-164	US- 6,169,087		01/02/2001	Andersen et al.	
	TR-165	US- 6,174,874		01/16/2001	Wang et al.	
	TR-166	US- 6,214,584		04/10/2001	Rodan et al.	
	TR-167	US- 6,238,902		05/29/2001	Cheng et al.	
	TR-169	US- 6,368,076		05/14/2002	Mjalli et al.	
	TR-170	US- 6,365,592		04/02/2002	Leblanc et al.	
	TR-171	US- 6,410,556		08/25/2002	Andersen et al.	
	TR-172	US- 6,448,428		09/10/2002	Leblanc et al.	
	TR-173	US- 6,465,444		10/15/2002	Bayty et al.	
	TR-174	US- 6,472,545		10/29/2002	Liu et al.	
	TR-175	US- 6,486,141		11/26/2002	Lau et al.	
	TR-176	US- 6,486,142		11/26/2002	Leblanc et al.	
	TR-177	US- 6,498,151		12/24/2002	Li et al.	
	TR-178	US- 6,534,056		03/18/2003	Tromblay et al.	
	TR-179	US- 6,583,126		06/24/2003	Leblanc et al.	
	TR-180	US- 6,566,467		07/01/2003	Burgess et al.	
LLS	TR-181	US- 6,596,772		07/22/2003	Huang et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴ - Number ⁴ - Kind Code ⁵ (if known)					

Examiner
Signature

/Laura L. Stockton/

Date
Considered

01/18/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 5 of 19**Complete If Known**

Application Number	10/777,488
Filing Date	02/12/04
First Named Inventor	Adnan M.M. Mjalli
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	TTP 2002-08

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
L.L.S. ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓ ↓	TR-182	US- 6,605,753	08/12/2003	Kennedy et al.	
	TR-183	US- 6,613,903	09/02/2003	Andersen et al.	
	TR-184	US- 6,627,767	09/30/2003	Liu et al.	
	TR-185	US- 6,699,898	03/02/2004	Malamas et al.	
	TR-186	US- 6,765,021	07/20/2004	Butera et al.	
	TR-187	US- 6,770,466	08/03/2004	Shi et al.	
	TR-188	US- 6,777,433	08/17/2004	Leblanc et al.	
	TR-189	US- 6,784,205	08/31/2004	Barr et al.	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ^o
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

Examiner
Signature

/Laura L. Stockton/

Date
Considered

01/18/2007


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US

PTO/SB/08a (08-03)



PTO/SB/08a (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

7

of

19

Complete If Known

Application Number	10/777,488
Filing Date	02/12/04
First Named Inventor	Adnan M.M. Mjalli
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	TTP 2002-08

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
LLS ↓ V	TR-211	US- 20040009946	01/15/2004	Lewis et al.	
	TR-212	US- 20040009956	01/15/2004	Pei et al.	
	TR-213	US- 20040014778	01/22/2004	Mjalli et al.	
	TR-214	US- 20040023974	02/05/2004	Coppola et al.	
	TR-215	US- 20040121353	08/24/2004	Lewis et al.	
	TR-216	US- 20040127570	07/01/2004	Mayer et al.	
	TR-217	US- 20040138218	07/15/2004	Pallen et al.	
	TR-218	US- 20040147596	07/29/2004	Barr et al.	
	TR-219	US- 20040147755	07/29/2004	Malamas et al.	
	TR-220	US- 20040167188	08/26/2004	Zhili et al.	
	TR-221	US- 20040176330	09/09/2004	Dufresne et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ^o
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				

Examiner
Signature

/Laura L. Stockton/

Date
Considered

01/18/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US



Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

Complete if Known

(Use as many sheets as necessary)

Sheet

8

of

19

Application Number

10777.488

Filing Date

02/12/04

First Named Inventor

Adnan M. M. Mialli

Art Unit

1614

Examiner Name

Unknown

Attorney Docket Number

TTP 2002-08

[illegible]

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
LLS	TR-134	EP 01019364	06/09/04	Larsen et al.		
V	TR-224	EP 1103180	05/30/01	Haap et al.		
	TR-228	EP 1227084	07/31/02	Leger et al.		
LLS	TR-222	EP 1402888	03/31/04	Knolle et al.		

**Examiner
Signature**

/Laura L. Stockton/

Date
Considered

01/18/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

9

of

9

Complete If Known

Application Number	10/777,488
Filing Date	02/12/04
First Named Inventor	Adnan M.M. Mjalli
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	TTP 2002-08

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LLS	TR-1	ANDERSEN HS, "2-(oxalylamino)-benzoic acid is a general, competitive inhibitor of protein-tyrosine phosphatases." The Journal of Biological Chemistry, 275:7101-7108 (2000)	
	TR-2	MURTHY VS, "3D-QSAR CoMFA and CoMSIA on Protein Tyrosine Phosphatase 1B Inhibitors" Bioorganic & Medicinal Chemistry, 10:2267-2282 (2002)	
	TR-3	MOK A, "A single nucleotide polymorphism in protein tyrosine phosphatase PTP-1B is associated with protection from diabetes or impaired glucose Tolerance in Oji-Cree" The Journal of Clinical Endocrinology & Metabolism, 87(2): 724-727 (2002)	
	TR-4	SHEN K, "Acquisition of a specific and potent PTP1B inhibitor from a novel combinatorial library and screening procedure." The Journal of Biological Chemistry, 276:47311-47319 (2001)	
	TR-5	COVIC L, "Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides." Proceedings of the National Academy of Sciences, 99:643-648 (2002)	
	TR-6	LIU DG, "Acylsulfonamide-containing PTP1B inhibitors designed to mimic an enzyme-bound water of hydration." Bioorganic & Medicinal Chemistry Letters, 13:3005-3007 (2003)	
	TR-7	WIESMANN C, "Allosteric inhibition of protein tyrosine phosphatase 1B" Nature Structural & Molecular Biology, 11:730-737 (2004)	
	TR-8	LI X, "Alpha, alpha-difluoro-beta-ketophosphonates as potent inhibitors of protein tyrosine phosphatase 1B." Bioorganic & Medicinal Chemistry Letters, 14:4301-4308 (2004)	
	TR-9	ARABACI G, "alpha-bromoacetophenone derivatives as neutral protein tyrosine phosphatase inhibitors: structure-Activity relationship." Bioorganic & Medicinal Chemistry Letters, 12:3047-3050 (2002)	
✓	TR-10	CHO KJ, "Alpha-lipoic acid decreases thiol reactivity of the Insulin receptor and protein tyrosine phosphatase 1B in 3T3-L1 adipocytes." Biochemical Pharmacology, 66:849-858 (2003)	
LLS	TR-11	AHMAD F, "Alterations in skeletal muscle protein-tyrosine phosphatase activity and expression in insulin-resistant human obesity and diabetes." Journal of Clinical Investigation, 100:449-458 (1997)	

Examiner Signature	/Laura L. Stockton/	Date Considered	01/18/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 10 of 19**Complete if Known**

Application Number	10/777,488
Filing Date	02/12/04
First Named Inventor	Adnan M.M. Mjalli
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	TTP 2002-08

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LLS	TR-12	WANG WQ, "An overview of the protein tyrosine phosphatase superfamily." Current Topics in Medicinal Chemistry, 3:739-748 (2003)	
	TR-13	GUM RJ, "Antisense Protein Tyrosine Phosphatase 1B Reverses Activation of p38 Mitogen-Activated Protein Kinase in Liver of ob/ob Mice." Molecular Endocrinology, 17:1131-1143 (2003)	
	TR-14	VETTER SW, "Assessment of protein-tyrosine phosphatase 1B substrate specificity using "inverse alanine scanning"." The Journal of Biological Chemistry, 275:2265-2268 (2000)	
	TR-15	PATANI G. "Bioisosterism: A Rational Approach in Drug Design." Chemical Review, 99, 3147-3176 (1998)	
	TR-16	LEE K, "CD45 protein-tyrosine phosphatase inhibitor development." Current Topics in Medicinal Chemistry, 3:797-807 (2003)	
	TR-17	IRIE-SASAKI J, "CD45 regulated signaling pathways." Current Topics in Medicinal Chemistry, 3:783-996 (2003)	
	TR-18	CHU W, "Cell-free Synthesis of Preparative Amounts of Enzymatically Active Human PTP1B" Biochemica, 2:28-29 (2001)	
	TR-19	XIE L, "Cellular effects of small molecule PTP1B inhibitors on insulin signaling." Biochemistry, 42:12792-12804 (2003)	
	TR-20	TAYLOR WP, "Charged with meaning: the structure and mechanism of phosphoprotein phosphatases." Chemistry & Biology, 2:713-718 (1995)	
	TR-21	PATANKAR SJ, "Classification of Inhibitors of Protein Tyrosine Phosphatase 1B Using Molecular Structure Based Descriptors " Journal of Chemical Information and Computer Sciences, 43:885-899 (2003)	
	TR-22	SUN JP, "Crystal structure of PTP1B complexed with a potent and selective bidentate inhibitor." The Journal of Biological Chemistry, 278:12408-12414 (2003)	
↓	TR-23	DATABASE CAPLUS "Online! Chemical Abstracts Service, Columbus, Ohio, US; HOSHINO, KAZUKI et al: "Anti-infective agents and drug efflux pump inhibitors containing heteroaromatic compounds and" retrieved from STN Database accession no. 2002: 849289 RN 3347904-05-9, RN 337903-86-5, abstract & JP 2002 322054, Japan; 8 November 2002	
LLS	TR-24	YAN Z, "Design and synthesis of phosphotyrosine mimetics." Bioorganic & Medicinal Chemistry Letters, 13:2083-2085 (2003)	


Examiner Signature	/Laura L. Stockton/	Date Considered	01/18/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US



PTO/SB/08b(08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

11

of

18

Complete if Known

Application Number	10/777,488
Filing Date	02/12/04
First Named Inventor	Adnan M.M. Mjalli
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	TTP 2002-08

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LLS	TR-25	ANDERSEN HS, "Discovery and SAR of a novel selective and orally bioavailable nonpeptide classical competitive inhibitor class of protein-tyrosine phosphatase 1B." Journal of Medicinal Chemistry, 45:4443-4459 (2002)	
	TR-26	PEI Z, "Discovery and SAR of novel, potent and selective protein tyrosine phosphatase 1B inhibitors." Bioorganic & Medicinal Chemistry Letters, 13:3129-3132 (2003)	
	TR-27	LIU G, "Discovery and structure-activity relationship of oxalylargininobenzonic acids as inhibitors of protein tyrosine phosphatase 1B." Journal of Medicinal Chemistry, 46:2093-2103 (2003)	
	TR-28	ERLANSON DA, "Discovery of a New Phosphotyrosine Mimetic for PTP1B Using Breakaway Tethering" Journal of the American Chemical Society, 125:5602-5603 (2003)	
	TR-29	HYAE GYEONG CHEON, "Discovery of a novel protein tyrosine phosphatase-1B inhibitor, KR61639: potential development as an antihyperglycemic agent" European Journal of Pharmacology, 485:333-339 (2004)	
	TR-30	OCKEY DA, "Discovery of novel PTP1b inhibitors " Bioorganic & Medicinal Chemistry Letters, 14:389-391 (2004)	
	TR-31	CHEN YT, "Divalent and trivalent alpha-ketocarboxylic acids as inhibitors of protein tyrosine phosphatases." Journal of Medicinal Chemistry, 45:3946-3952 (2002)	
	TR-32	BOUTE N, "Dynamics of the interaction between the insulin receptor and protein tyrosine-phosphatase 1B in living cells." EMBO Reports, 4:313-319 (2003)	
	TR-33	PETRONE A, "Emerging issues in receptor protein tyrosine phosphatase function: lifting fog or simply shifting?" Journal of Cell Science, 113:2345-2354 (2000)	
	TR-34	PETERS GH, "Enzyme kinetic characterization of protein tyrosine phosphatases" Biochimie, 85:527-534 (2003)	
LLS	TR-35	SHRESTHA S, "Evans Blue and other dyes as protein tyrosine phosphatase inhibitors." Bioorganic & Medicinal Chemistry Letters, 14:1923-1926 (2004)	

Examiner Signature	/Laura L. Stockton/	Date Considered	01/18/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
Application Number		10/777,488	
Filing Date		02/12/04	
First Named Inventor		Adnan M.M. Mjalli	
Art Unit		1614	
Examiner Name		Unknown	
Attorney Docket Number		TTP 2002-08	
Sheet	12	of	19

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LLS	TR-36	CROSS KP, "Finding discriminating structural features by reassembling common building blocks." Journal of Medicinal Chemistry, 46:4770-4775 (2003)	
	TR-37	WANG Q, "Fluorescein monophosphates as fluorogenic substrates for protein tyrosine phosphatases." Biochimica Et Biophysica Acta, 1431:14-23 (1999)	
	TR-38	SHIM YS, "Formylchromone derivatives as a novel class of protein tyrosine phosphatase 1B inhibitors." Bioorganic & Medicinal Chemistry Letters, 13:2561-2563 (2003)	
	TR-39	LIU G, "Fragment screening and assembly: a highly efficient approach to a selective and cell active protein tyrosine phosphatase 1B inhibitor." Journal of Medicinal Chemistry, 46:4232-4235 (2003)	
	TR-40	ROMSICKI Y, "Functional characterization and crystal structure of the C215D mutant of protein-tyrosine phosphatase-1B." The Journal of Biological Chemistry, 278:29009-15 (2003)	
	TR-41	PHAN J, "High-Resolution Structure of the Yersinia pestis Protein Tyrosine Phosphatase YopH in Complex with a Phosphotyrosyl Mimetic-Containing Hexapeptide." Biochemistry, 42:13113-13121 (2003)	
	TR-42	XIN Z, "Identification of a monoacid-Based, cell permeable, selective inhibitor of protein tyrosine phosphatase 1B." Bioorganic & Medicinal Chemistry Letters, 13:3947-3950 (2003)	
	TR-43	PUIUS YA, "Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: a paradigm for inhibitor design." Proceedings of the National Academy of Sciences, 94:13420-13425 (1997)	
	TR-44	FUKADA T, "Identification of YB-1 as a regulator of PTP1B expression: implications for regulation of insulin and cytokine signaling." The EMBO Journal, 22:479-493 (2003)	
	TR-45	ELCHEBLY M, "Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene." Science, 283:1544-1548 (1999)	
LLS	TR-46	ZABELL AP, "Inhibition studies with rationally designed inhibitors of the human low molecular weight protein tyrosine phosphatase." Bioorganic & Medicinal Chemistry, 12:1867-1880 (2004)	


Examiner Signature	/Laura L. Stockton/	Date Considered	01/18/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US



PTO/SB/08b(08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/777,421
		Filing Date	02/04/04
		First Named Inventor	Adnan M.M. Mjalli
		Art Unit	1615
		Examiner Name	Unknown
Sheet	13 of 19	Attorney Docket Number	TTP 2002-07

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LLS	TR-59	DOMAN TN, "Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B." Journal of Medicinal Chemistry, 45:2213-2221 (2002)	
	TR-60	PETERS GH, "Molecular dynamics simulations of protein-tyrosine phosphatase 1B. I. ligand-induced changes in the protein motions." Biophysical Journal, 77:505-515 (1999)	
	TR-61	PETERS GH, "Molecular dynamics simulations of protein-tyrosine phosphatase 1B. II. substrate-enzyme interactions and dynamics." Biophysical Journal, 78:2191-2200 (2000)	
	TR-62	MALAMAS MS, "New azolidinediones as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties." Journal of Medicinal Chemistry, 43:995-1010 (2000)	
	TR-63	MALAMAS MS, "Novel benzofuran and benzothiophene biphenyls as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties." Journal of Medicinal Chemistry, 43:1293-1310 (2000)	
	TR-234	MEANWELL et al., "Nonprostanoid Prostacyclin Mimetics. 2. 4,5-Diphenyloxazole Derivatives", Journal of Medicinal Chemistry, Vol. 35, pages 3483-3497 (1992)	
	TR-64	GLOVER NR, "Nuclear magnetic resonance and restrained molecular dynamics studies of the interaction of an epidermal growth factor-derived peptide with protein tyrosine phosphatase 1B." Biochemistry, 38:5256-5271 (1999)	
	TR-65	LILJEBRIS C, "Oxidation of protein tyrosine phosphatases as a pharmaceutical mechanism of action: a study using 4-hydroxy-3,3-dimethyl-2H-benzo[g]indole-2,5(3H)-dione." The Journal of Pharmacology & Experimental Therapeutics, 309:711-719 (2004)	
	TR-66	VAN MONTFORT RL, "Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B." Nature, 423:773-777 (2003)	
	TR-67	CHEN YT, "Parallel synthesis of a library of bidentate protein tyrosine phosphatase inhibitors based on the alpha-ketoacid motif." Bioorganic & Medicinal Chemistry, 12:3289-3298 (2004)	
↓	TR-68	CHEN YT, "Peptidic alpha-Ketocarboxylic Acids and Sulfonamides as Inhibitors of Protein Tyrosine Phosphatases." Journal of Organic Chemistry, 68:4123-4125 (2003)	
LLS	TR-69	TAING M, "Potent and highly selective inhibitors of the protein tyrosine phosphatase 1B" Biochemistry, 38:3793-3803 (1999)	

Examiner Signature	/Laura L. Stockton/	Date Considered	01/18/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US



PTO/SB/08b(08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 14 of 19

Complete if Known

Application Number	10/777,488
Filing Date	02/12/04
First Named Inventor	Adnan M.M. Mjalli
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	TTP 2002-08

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LLS	TR-70	URBANEK, "Potent Reversible Inhibitors of the Protein Tyrosien Phosphatase CD45" Journal of Medical Chemistry, 44: 1777-1793 (2001)	
	TR-71	XIN Z, "Potent, selective inhibitors of protein tyrosine phosphatase 1B." Bioorganic & Medicinal Chemistry Letters, 13:1887-1890 (2003)	
	TR-72	GUO XL, "Probing the molecular basis for potent and selective protein-tyrosine phosphatase 1B inhibition." The Journal of Biological Chemistry, 277:41014-41022 (2002)	
	TR-73	HOOFT VAN HUIJSDUIJNEN R, "Prospects for inhibitors of protein tyrosine phosphatase 1B as antidiabetic drugs." Journal of Medicinal Chemistry, 47:4142-4148 (2004)	
	TR-74	LIU G, "Protein tyrosine phosphatase 1B inhibition: opportunities and challenges." Current Medicinal Chemistry, 10:1407-1421 (2003)	
	TR-75	JOHNSON TO, "Protein tyrosine phosphatase 1B inhibitors for diabetes" Nature Reviews Drug Discovery, 1:698-709 (2002)	
	TR-76	RONDINONE CM, "Protein tyrosine phosphatase 1B reduction regulates adiposity and expression of genes involved in lipogenesis." Diabetes, 51:2405-2411 (2002)	
	TR-77	RAMACHANDRAN C, "Protein tyrosine phosphatase 1B: a novel target for type 2 diabetes and obesity." Current Topics in Medicinal Chemistry, 3:749-757 (2003)	
	TR-78	ROMSICKI Y, "Protein Tyrosine Phosphatase-1B Dephosphorylation of the Insulin Receptor Occurs in a Perinuclear Endosome Compartment in Human Embryonic Kidney 293 Cells." The Journal of Biological Chemistry, 279:12868-12875 (2004)	
	TR-79	WU ZL, "Protein tyrosine phosphatases are up-regulated and participate in cell death induced by polyglutamine expansion." The Journal of Biological Chemistry, 277:44208-44213 (2002)	
↓	TR-80	ALONSO A, "Protein tyrosine phosphatases in the human genome." Cell, 117:699-711 (2004)	
LLS	TR-81	ZHANG ZY, "PROTEIN TYROSINE PHOSPHATASES: Structure and Function, Substrate Specificity, and Inhibitor Development" Annual Review of Pharmacology and Toxicology, 42:209-234 (2002)	

Examiner Signature	/Laura L. Stockton/	Date Considered	01/18/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US



PTO/SB/08b(08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

15

of

19

Complete if Known

Application Number	10/777,488
Filing Date	02/12/04
First Named Inventor	Adnan M.M. Mjalli
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	TTP 2002-08

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LLS	TR-82	GOLDSTEIN BJ, "Protein-tyrosine phosphatase 1B (PTP1B): a novel therapeutic target for type 2 diabetes mellitus, obesity and related states of insulin resistance." Current Drug Targets - Immune, Endocrine & Metabolic Disorders, 1:265-275 (2001)	
	TR-83	DADKE S; CHERNOFF J, "Protein-Tyrosine Phosphatase 1B as a Potential Drug Target for Obesity" Current Drug Targets - Immune, Endocrine & Metabolic Disorders, 3:299-304 (2003)	
	TR-84	SHIMIZU S, "Protein-tyrosine Phosphatase 1B as New Activator for Hepatic Lipogenesis via Sterol Regulatory Element-binding Protein-1 Gene Expression." The Journal of Biological Chemistry, 278:43095-43101 (2003)	
	TR-85	DADKE S, "Protein-tyrosine phosphatase 1B mediates the effects of insulin on the actin cytoskeleton in immortalized fibroblasts." The Journal of Biological Chemistry, 278:40607-40611 (2003)	
	TR-86	GOLDSTEIN BJ, "Protein-tyrosine phosphatases: emerging targets for therapeutic intervention in type 2 diabetes and related states of insulin resistance" The Journal of Clinical Endocrinology & Metabolism, 87:2474-2480 (2002)	
	TR-88	ZINKER BA, "PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice." Proceedings of the National Academy of Sciences, 99:11357-11362 (2002)	
	TR-89	WARING JF, "PTP1B antisense-treated mice show regulation of genes involved in lipogenesis in liver and fat." Molecular and Cellular Endocrinology, 203:155-168 (2003)	
	TR-90	TONKS NK, "PTP1B: from the sidelines to the front lines" FEBS Letters, 546:140-148 (2003)	
	TR-91	ROMSICKI Y, "Purification and characterization of T cell protein tyrosine phosphatase reveals significant functional homology to protein tyrosine phosphatase-1B." Archives of Biochemistry and Biophysics, 414:40-50 (2003)	
↓	TR-92	SALMEEN A, "Redox regulation of protein tyrosine phosphatase 1B involves a sulphenyl-amide intermediate." Nature, 423:769-773 (2003)	
LLS	TR-93	GUM RJ, "Reduction of protein tyrosine phosphatase 1B increases insulin-dependent signaling in ob/ob mice." Diabetes, 52:21-28 (2003)	

Examiner
Signature

/Laura L. Stockton/

Date
Considered

01/18/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US



PTO/SB/08b(08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 6 of 19

Complete if Known

Application Number	10/777,488
Filing Date	02/12/04
First Named Inventor	Adnan M.M. Mjalli
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	TTP 2002-08

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LLS	TR-94	GALIC S, "Regulation of insulin receptor signaling by the protein tyrosine phosphatase TCPTP." Molecular And Cellular Biology, 23:2098-2108 (2003)	
	TR-95	HAJ FG, "Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatase-1B." The Journal of Biological Chemistry, 278:739-44 (2003)	
	TR-96	PETERS GH, "Residue 259 is a key determinant of substrate specificity of protein-tyrosine phosphatases 1B and alpha." The Journal of Biological Chemistry, 275:18201-18209 (2000)	
	TR-97	LIU G, "Selective protein tyrosine phosphatase 1B inhibitors: targeting the second phosphotyrosine binding site with non-carboxylic acid-containing ligands." Journal of Medicinal Chemistry, 46:3437-3440 (2003)	
	TR-98	MILARSKI KL, "Sequence specificity in recognition of the epidermal growth factor receptor by protein tyrosine phosphatase 1B." The Journal of Biological Chemistry, 268:23634-23639 (1993)	
	TR-99	HALAZY S, "Signal Transduction: An Exciting Field of Investigation for Small Molecule Drug Discovery" Molecules, 8:349-358 (2003)	
	TR-100	BLEASDALE JE, "Small molecule peptidomimetics containing a novel phosphotyrosine bioisostere inhibit protein tyrosine phosphatase 1B and augment insulin action." Biochemistry, 40:5642-5654 (2001)	
	TR-229	CESCON GR, "Some Properties of Triarylimidazolyl Radicals and Their Dimers" Journal of Organic Chemistry, Vol. 36, No. 18, (1971)	
	TR-101	XIE J, "Squaric Acids: A New Motif for Designing Inhibitors of Protein Tyrosine Phosphatases " Organic Letters, 8:83-86 (2004)	
	TR-102	DILLET V, "Stabilization of Charges and Protonation States in the Active Site of the Protein Tyrosine Phosphatases: A Computational Study" Journal of Physical Chemistry B, 104:11321-11333 (2000)	
✓	TR-103	IVERSEN LF, "Steric hindrance as a basis for structure-based design of selective inhibitors of protein-tyrosine phosphatases." Biochemistry, 40:14812-14820 (2001)	
LLS	TR-104	ANDERSEN JN, "Structural and evolutionary relationships among protein tyrosine phosphatase domains." Molecular And Cellular Biology, 21:7117-7138 (2001)	

Examiner Signature	/Laura L. Stockton/	Date Considered	01/18/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US



PTO/SB/08b(08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 17 of 19

Complete If Known

Application Number	10/777,488
Filing Date	02/12/04
First Named Inventor	Adnan M.M. Mjalli
Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	TTP 2002-08

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LLS	TR-105	GROVES M, "Structural Basis for Inhibition of the Protein Tyrosine Phosphatase 1B by Phosphotyrosine Peptide Mimetics" Biochemistry, 37:17773-17783 (1998)	
	TR-106	SARMIENTO M, "Structural basis of plasticity in protein tyrosine phosphatase 1B substrate recognition" Biochemistry, 39:8171-8179 (2000)	
	TR-107	LAU C, "Structure based design of a series of potent and selective non peptidic PTP-1B Inhibitors" Bioorganic & Medicinal Chem. Letters, 14: 1043-4048 (2004)	
	TR-108	VERSEN LF, "Structure determination of T cell protein-tyrosine phosphatase." The Journal of Biological Chemistry, 277:19982-19990 (2002)	
	TR-109	JIA Z, "Structure of protein tyrosine phosphatase 1B in complex with inhibitors bearing two phosphotyrosine mimetics." Journal of Medicinal Chemistry, 44:4584-4594 (2001)	
	TR-110	IVERSEN LF, "Structure-based design of a low molecular weight, nonphosphorus, nonpeptide, and highly selective inhibitor of protein-tyrosine phosphatase 1B." The Journal of Biological Chemistry, 275:10300-10307 (2000)	
	TR-111	LUND IK, "Structure-based design of selective and potent inhibitors of protein-tyrosine phosphatase beta." The Journal of Biological Chemistry, 279:24226-24235 (2004)	
	TR-112	SARMIENTO M, "Structure-based discovery of small molecule inhibitors targeted to protein tyrosine phosphatase 1B." Journal of Medicinal Chemistry, 43:146-155 (2000)	
	TR-113	WANG J, "Structure-based Prediction of Free Energy Changes of binding of PTP1B Inhibitors" Journal of Computer-Aided Molecular Design, 17:495-513 (2003)	
	TR-114	MCCAIN DF, "Suramin derivatives as inhibitors and activators of protein-tyrosine phosphatases." The Journal of Biological Chemistry, 279:14713-14725 (2004)	
	TR-115	LILJEBRIS C, "Synthesis and biological activity of a novel class of pyridazine analogues as non-competitive reversible inhibitors of protein tyrosine phosphatase 1B (PTP1B)." Bioorganic & Medicinal Chemistry, 10:3197-3212 (2002)	
✓	TR-116	LARSEN SD, "Synthesis and biological activity of a novel class of small molecular weight peptidomimetic competitive inhibitors of protein tyrosine phosphatase 1B" Journal of Medicinal Chemistry, 45:598-622 (2002)	
LLS	TR-117	THERIEN M, "Synthesis of a novel peptidic photoaffinity probe for the PTP-1B enzyme." Bioorganic & Medicinal Chemistry Letters, 14:2319-2322 (2004)	

Examiner
Signature

/Laura L. Stockton/

Date
Considered


01/18/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US



PTO/SB/08b(08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/777,488
		Filing Date	02/12/04
		First Named Inventor	Adnan M.M. Mjalli
		Art Unit	1614
		Examiner Name	Unknown
Sheet 18 of 19	Attorney Docket Number TTP 2002-08		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LLS	TR-118	DUFRESNE C, "The development of potent non-peptidic PTP-1B inhibitors." Bioorganic & Medicinal Chemistry Letters, 14:1039-1042 (2004)	
	TR-119	LEUNG C, "The difluoromethylenesulfonic acid group as a monoanionic phosphate surrogate for obtaining PTP1B inhibitors." Bioorganic & Medicinal Chemistry, 10:2309-2323 (2002)	
	TR-120	MOONEY RA, "The leukocyte common antigen-related protein LAR: candidate PTP for inhibitory targeting." Current Topics in Medicinal Chemistry, 3:809-819 (2003)	
	TR-122	TIGANIS T, "The protein-tyrosine phosphatase TCPTP regulates epidermal growth factor receptor-mediated and phosphatidylinositol 3-kinase-dependent signaling." The Journal of Biological Chemistry, 274:27768-27775 (1999)	
	TR-123	WIDLANSKI TS, "The road less travelled: taming phosphatases." Chemistry & Biology, 4:489-492 (1997)	
	TR-124	DUBE N, "The role of protein tyrosine phosphatase 1B in Ras signaling." Proceedings of the National Academy of Sciences, 101:1834-1839 (2004)	
	TR-125	ESPANEL X, "The SPOT technique as a tool for studying protein tyrosine phosphatase substrate specificities." Protein Science, 11:2326-2334 (2002)	
	TR-126	SCAPIN G, "The structural basis for the selectivity of benzotriazole inhibitors of PTP1B." Biochemistry, 42:11451-11459 (2003)	
	TR-127	ASANTE-APPIAH E, "The structure of PTP-1B in complex with a peptide inhibitor reveals an alternative binding mode for bisphosphonates." Biochemistry, 41:9043-9051 (2002)	
✓	TR-128	BUKCYNSKA P, "The T-cell protein tyrosine phosphatase is phosphorylated on Ser-304 by cyclin-dependent protein kinases in mitosis." Biochemical Journal, 380:939-949 (2004)	
LLS	TR-129	RAGAB A, "The tyrosine phosphatase 1B regulates linker for activation of T-cell phosphorylation and platelet aggregation upon FcγRIIIa cross-linking." The Journal of Biological Chemistry, 278:40923-40932 (2003)	

Examiner Signature	/Laura L. Stockton/	Date Considered	01/18/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/777,488		
		Filing Date	02/12/04		
		First Named Inventor	Adnan M.M. Mjalli		
		Art Unit	1614		
		Examiner Name	Unknown		
Sheet	19	of	19	Attorney Docket Number	TTP 2002-08

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
LLS	TR-130	ZABOLOTNY JM, "Transgenic Overexpression of Protein-tyrosine Phosphatase 1B in Muscle Causes Insulin Resistance, but Overexpression with Leukocyte Antigen-related Phosphatase Does Not Additively Impair Insulin Action." The Journal of Biological Chemistry, 279:24844-24851 (2004)	
	TR-131	LEE K, "Tripeptide inhibitors of Yersinia protein-tyrosine phosphatase." Bioorganic & Medicinal Chemistry Letters, 13:2577-2581 (2003)	
	TR-132	SIMS C, "Tyrosine phosphatase inhibitors selectively antagonize beta-adrenergic receptor-dependent regulation of cardiac ion channels." Molecular Pharmacology, 58:1213-1221 (2000)	
LLS	TR-133	ZHU L, "Use of an Anaerobic Chamber Environment for the Assay of Endogenous Cellular Protein-Tyrosine Phosphatase Activities." Biological Procedures Online, 4:1-9 (2002)	

Examiner Signature	/Laura L. Stockton/	Date Considered	01/18/2007
--------------------	---------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EV 507590141 US